StoneX Group clearly didn’t skip leg day—it just bulked up its Pfizer holdings by a massive 43.5% in Q4, scooping up over ...

Representative Rob Bresnahan, Jr. of Pennsylvania recently made headlines—not for legislation, but for investing between ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports.